NSABP Members' Area   Password Protected - Access   Limited to NSABP Participating   Institutions Only NSABP Foundation, Inc. General NSABP Information   Contact the NSABP   Pathology Section   Future Meetings   NSABP Newsletters   Media Info on cMYC Study   Media Info on STAR   Employment Clinical Trials Information   Clinical Trials Overview   Protocol Chart   Never Say Lost Treatment Trials Information   Protocol B-36   Protocol B-37   Protocol B-39   Protocol B-40   Protocol B-41   Protocol B-42   Protocol C-10   Protocol R-04 Prevention Trials Information   Protocol P-1 - BCPT   Protocol P-2 - STAR   BreastCancerPrevention.com Bibliography of Publications Related Web Sites About the NSABP Web Site Helper Applications Links to Major Search Engines Medical Search Engines To report problems, ask questions or make comments, please send e-mail to: Webmaster@nsabp.pitt.edu

NSABP Clinical Trials Overview Protocol B-40 A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens Specific Aims The primary aims of this Phase III study are to determine whether adding capecitabine or gemcitabine to docetaxel followed by AC will increase the pathologic complete response (pCR) rates in patients with palpable and operable HER2-negative breast cancer and to determine whether the addition of bevacizumab to three docetaxel-based regimens followed by AC will increase pCR rates.